Preclinical assessment of dual CYP26[A1/B1] inhibitor, DX308, as an improved treatment for keratinization disorders.

ABSTRACT:

Background

Retinoid-based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non-specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may address these shortcomings.

Objectives

Characterize the therapeutic potential of recently discovered, CYP26-selective RAMBA, DX308.

Materials and methods

Preliminary in vitro assessment of potential off-target activity, metabolic and toxicologic profiling. Studies to assess safety and efficacy of topical treatment in correcting abnormal skin morphology in rhino mice. Extensive gene expression profiling by RNA sequencing and qPCR in 3D epidermis grown with keratinocytes (KCs) from keratinization disorders and

SUBMITTER: Veit JGS 

PROVIDER: S-EPMC9060145 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature